Now, Genexine a Korean Biopharma company have published exciting results of a phase 1 study of a therapeutic vaccine candidate, GX-188E. The vaccine is an immunotherapeutic vaccine and was given to women with biopsy-proven CIN 3 (the most advanced grade of pre-cancerous tissue)
Promising results for therapeutic HPV vaccine
The vaccine resulted in complete viral clearance in conjunction with lesion regression in 7 out of the 9 participants in the study. The patients were given 3 injections over 12 weeks. By week 36 lesions were completely gone in 7 of the patients and there have been no cases of lesion recurrence up to 1 year post-administration. The vaccine also appeared safe with few side effects s
There have been several studies of vaccine candidates for HPV but so far none of them has yielded efficacy rates above 50%. This is one of the first studies that have had such a high success rate and in addition evidence that the vaccine elicits specific T cell response by targeting HPV antigens in dendritic cells.
The team are now performing a phase 2 clinical trail with 72 patients who have CIN and other studies are expected to start in Europe in 2015
If the results can be replicated it would be great news for the thousands of people affected by HPV and importantly could give us a treatment that can cure HPV-related cervical, anal and other cancers